A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors
Status:
Withdrawn
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended Phase 2 dose for PF-03084014
single-agent administration in Japanese patients with advanced solid tumors. Pharmacokinetics
and the overall safety profile of PF-03084014 will also be evaluated.